ImmunityBio (IBRX) is down sharply as the market re-prices regulatory and legal risk stemming from FDA enforcement actions focused on ANKTIVA promotion. The company previously disclosed it responded to FDA correspondence and said it implemented corrective actions aimed at ensuring promotional materials are accurate and compliant, but the episode continues to weigh on sentiment and adds perceived headline risk for a high-volatility biotech name. (ir.immunitybio.com)

In recent sessions, multiple investor-law-firm notices have spotlighted an ongoing securities class action tied to the same FDA warning-letter episode and the stock’s late-March drawdown, keeping the issue in front of traders even without a new clinical readout. The repeated reminders about lead-plaintiff deadlines are acting as a sentiment drag and can pressure marginal buyers who are waiting for clearer resolution on regulatory scrutiny. (globenewswire.com)

IBRX has also been showing heightened options-related churn, which can magnify intraday swings when headlines turn negative and hedging flows accelerate. With shares already sensitive to regulatory updates, this options activity is contributing to the air-pocket style move. (tipranks.com)

Traders are likely to focus on any follow-on FDA communications or additional company updates about promotional remediation and marketing practices, plus any incremental court developments in the securities case. Any clarity that the promotional-compliance dispute is contained—or, conversely, any sign of escalation—could quickly shift the stock given its headline sensitivity. (ir.immunitybio.com)